Swiss biotech startup from Zurich, Switzerland

We present here a list of biotech startups located in the Zurich area. As the two major institutions in Zurich area are ETH Zurich and the University of Zurich, many of these startups are linked to these organizations (i.e. with spin-off companies).

ETH Zurich, Zurich, Switzerland

Araris Biotech (see their website) – Founded: 2019 – Location: Zurich (ZH)
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology.
Araris Biotech is backed by a strong investor syndicate: Pureos Bioventures (VC company located in Switzerland), 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq, acording to its website (Jan. 2022).
In 2020, the company raised CHF 15.2M. In 2021, Araris ranked TOP11 at Swiss startup Award 2021 (number 3 in Biotech industry).

CUTISS (see their website) – Founded (incorporated): 2017 – Location: Schlieren (ZH)
CUTISS AG is a spin-off company from the University of Zurich. The company grows human skin in the lab for patients that suffer from skin defects (e.g. burns). 
In 2020 the company raised CHF 20 million in a Series B1.
In 2021, CUTISS ranked TOP2 at Swiss startup Award 2021 (number 1 in Biotech industry). January 21, 2022 the company had no vacancies, according to its website.

Numab (see their website) – Founded (incorporated): 2016 – Location: Wädenswil (ZH)
Numab Therapeutics AG is a Swiss biotech company that innovates and develops antibody-based therapeutics. A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane proteins. 
In 2021, Numab Therapeutics completes oversubscribed CHF 100 million Series C financing2.
In 2021, Numab ranked TOP50 at Swiss startup Award 2021.

More ressources:

Read also:
Swiss biotech startup from Basel, Switzerland

January 27, 2022. By Xavier Gruffat (pharmacist, ETH Zurich).

Did you find this article useful?

  1. Series B financing oversubscribed, June 29, 2020
  2. Numab Therapeutics completes oversubscribed CHF 100 million Series C financing, 20.05.2021
Informations sur la rédaction de cet article et la date de la dernière modification: 27.01.2022